Last-Resort cancer therapy made available to patients with no other options
NCT ID NCT03601442
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides early access to CTL019, a cell therapy that reprograms a patient's own immune cells to attack cancer. It is for people with lymphoma or leukemia who have no other treatment choices and cannot join a clinical trial. The goal is to offer a potential benefit when standard options are exhausted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CTL019 (tisagenlecleucel), a type of cell therapy that uses a patient's own immune cells to fight cancer
What this could lead to
If successful, this program could offer a lifeline to patients with serious blood cancers who have run out of standard treatments.
What could go wrong
This is not a clinical trial but an early-access program, so data on safety and effectiveness is limited. The therapy may not work for everyone and carries risks like severe immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••